By: Ed Susman
— Intranasal bumetanide demonstrated safety, bioequivalence with its oral and IV counterparts
United States (National)
Not enough data
Ed’s coverage is heavily focused on medical research, diseases, treatment options, vaccines, and medical procedures. His articles often cite data to support the claims made. Given this emphasis on evidence-based reporting, Ed would likely be most interested in receiving pitches from sources who can provide access to or insights into new studies or datasets related to medical research and healthcare.
Considering his focus on scientific themes and heavy reliance on data citing indicates that he might highly appreciate being pitched with exclusive access to new findings or experts who have unique insights backed by robust evidence. This could include researchers involved in groundbreaking studies or professionals at the forefront of innovative treatments for various diseases.
Ed does not appear to have a specific geographic focus but covers topics that are universally applicable within the field of healthcare and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .